YMAB stock forecast
Our latest prediction for Y-mAbs Therapeutics, Inc.'s stock price was made on the Aug. 30, 2019 when the stock price was at 26.57$.
In the short term (2weeks), YMAB's stock price should underperform the market by -0.78%. During that period the price should oscillate between -8.40% and +9.31%.
In the medium term (3months), YMAB's stock price should outperform the market by 2.44%. During that period the price should oscillate between -18.62% and +27.62%.Get email alerts
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.11$ per share.
The book value per share is 4.11$
Three months stock forecastAug. 30, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|